Wegovy for Alcohol Use Disorder: What Insurance Actually Covers and What You Will Pay

What Is the Current Evidence That Wegovy Reduces Alcohol Use?

The short answer: the evidence is early, real, and encouraging, but still preliminary. Wegovy is not approved by the FDA for alcohol use disorder (AUD), and calling it a proven AUD treatment would go further than the data support right now.

The Hendershot Trial (NEJM Evidence, 2024)

The study that generated the most attention was published in NEJM Evidence in January 2024. Christian Hendershot and colleagues ran a 9-week randomized, double-blind, placebo-controlled trial in 48 adults with AUD. Participants receiving weekly semaglutide (doses up to 1.0 mg, the Ozempic tier rather than full Wegovy 2.4 mg) drank significantly fewer drinks per week than those on placebo. They also reported lower urge to drink after viewing alcohol cues. The trial was small, short, and performed mostly in men, which matters for how you interpret results as a woman.

The Mechanistic Argument

GLP-1 receptors sit in the mesolimbic dopamine pathway, the same circuit that processes reward from alcohol, food, and other substances. Preclinical rodent studies have shown that GLP-1 agonists reduce voluntary alcohol consumption, and human neuroimaging work suggests attenuated reward-center activation. The biology is plausible. Whether semaglutide at the full 2.4 mg Wegovy dose replicates and magnifies these effects in a larger, longer, female-inclusive trial is the open question.

What Is Still Missing

No large Phase 3 trial has reported results specifically for semaglutide 2.4 mg in AUD. The ongoing NIAAA-funded STAR trial (NCT05520138) is designed to answer that question with a larger sample and longer duration, but data are not yet published. Women with AUD were under-represented in the Hendershot pilot. Female-specific PK data for semaglutide in AUD contexts (cycling estrogen, perimenopause, or postpartum status affecting alcohol metabolism and GLP-1 receptor sensitivity) have not been systematically studied. That gap is real and worth naming plainly.

Off-Label Status: What It Means Practically for You

"Off-label" means a prescriber can legally write the prescription, but the FDA has not reviewed or approved the drug for that specific use. Wegovy's only approved indication is chronic weight management in adults with a BMI of 30 or higher, or 27 or higher with at least one weight-related comorbidity.

Off-label prescribing is common and legal. Roughly 20 percent of all prescriptions written in the United States are off-label. The clinical and legal risk falls on the prescribing clinician, who must document medical rationale. The financial risk falls almost entirely on you, because insurers almost always deny off-label claims for expensive biologics.

What "Off-Label" Does Not Mean

It does not mean dangerous or experimental in the sense of uncharted territory. Semaglutide's safety profile is well characterized from large cardiovascular outcome trials including SUSTAIN-6 and the SELECT trial, which enrolled over 17,600 participants. Those trials inform what is known about nausea, pancreatitis risk, thyroid C-cell concerns, and drug interactions. The safety data exist. The AUD efficacy data are what remain thin.

Insurance Coverage Reality: Why Almost No Plan Pays for This

This is the section most articles skip or soften. Here is the direct reality.

The Weight-Indication Loophole Does Not Apply Here

Some women wonder whether they can get Wegovy covered under its obesity indication and use it for AUD simultaneously. This works only if you independently qualify for weight management coverage under your specific plan, meaning you meet BMI criteria and your plan covers GLP-1s for obesity, which many employer plans still explicitly exclude. Even then, the prescription is being approved for weight, not for AUD, and any documentation tying it to AUD could trigger a denial or recoupment.

Prior Authorization Criteria You Will Face

For the small number of plans that cover Wegovy at all, prior authorization typically requires:

• Documented BMI of 30 or a BMI of 27 with a qualifying comorbidity (hypertension, type 2 diabetes, dyslipidemia, sleep apnea)
• Failure or contraindication to lifestyle intervention programs
• No active or planned pregnancy
• Often: step therapy through bupropion-naltrexone (Contrave) or other agents first

Alcohol use disorder is not on that list. A prescriber submitting a prior auth citing AUD as the primary indication will almost certainly receive a denial. An appeal citing the Hendershot pilot data may occasionally succeed at plans with a medical-exception pathway, but success rates are low and the process takes weeks.

Medicaid and Medicare Coverage

Medicaid coverage of GLP-1s for obesity varies sharply by state, and almost no state Medicaid plan covers Wegovy for an off-label indication like AUD. Medicare Part D plans were barred from covering weight-loss drugs until the Treat and Reduce Obesity Act provisions under consideration; coverage for AUD would require a separate FDA approval that does not exist.

Real Costs: What You Can Expect to Pay

List Price vs. Net Price

Novo Nordisk's list price for Wegovy in the United States is approximately $1,349 per 28-day supply at the 2.4 mg maintenance dose, though pharmacy-negotiated prices vary and the net price after rebates is lower. What you pay out of pocket depends on which of several pathways applies to you.

Pathway 1: Novo Nordisk Savings Card (Commercially Insured)

Novo Nordisk offers a savings card that can reduce your monthly cost to as low as $0 for eligible commercially insured patients. The critical condition: your plan must cover Wegovy (for weight management). If your plan excludes it, the card does not apply. Many women pursuing Wegovy for AUD without a qualifying obesity diagnosis find they do not meet the card eligibility criteria.

Pathway 2: Cash Pay Without Assistance

Without insurance or a savings card, you are looking at $1,349 to $1,700 per month depending on the pharmacy and your location. At 12 months of treatment, that is $16,000 to $20,400 out of pocket. GoodRx coupons can bring the price to approximately $1,100 to $1,200 at some pharmacies, but they do not stack with the manufacturer card or insurance.

Pathway 3: Compounded Semaglutide

When Wegovy appeared on the FDA drug shortage list, compounding pharmacies were permitted to prepare semaglutide formulations. The FDA removed Wegovy from the shortage list in February 2025, after which it issued guidance that most compounding of semaglutide by 503A pharmacies must cease. Some 503B outsourcing facilities continue to operate. Compounded semaglutide, when available, has been priced at $200 to $500 per month, but quality, sterility, and dosing accuracy are not federally regulated the same way branded products are. This is a real tradeoff to discuss with your clinician.

Pathway 4: Clinical Trials

If you meet eligibility criteria, enrolling in a clinical trial may be the most cost-effective and medically supervised option. The STAR trial and related studies provide the drug at no cost. ClinicalTrials.gov is the most reliable place to search current enrollment status.

Women-Specific Considerations Across Life Stages

Reproductive Years and Menstrual Cycle Effects

Women in their reproductive years clear alcohol differently than men at every phase of the cycle. Higher estrogen levels in the follicular phase are associated with greater alcohol sensitivity, partly because women have lower gastric alcohol dehydrogenase activity than men do. This pharmacokinetic difference means women reach higher blood alcohol concentrations per gram of alcohol consumed per kilogram of body weight. If semaglutide reduces craving partly through appetite and reward center modulation, cycling estrogen may interact with that effect in ways no published trial has yet characterized.

Perimenopause: Elevated AUD Risk

Women in perimenopause face a convergence of risk factors. Sleep disruption, mood dysregulation, and vasomotor symptoms all correlate with increased alcohol use as a coping strategy. The NIAAA reports that alcohol use disorder among midlife women is rising faster than in almost any other demographic. Perimenopause is also the life stage when hormonal shifts alter GLP-1 receptor signaling and body composition, both of which could affect semaglutide's action. No semaglutide AUD trial has stratified by menopausal status.

Postpartum and Lactation

Postpartum alcohol use disorder is under-recognized. Women in the postpartum period should know that semaglutide transfers into breast milk in animal studies, and human lactation data are absent. The FDA label states the drug should not be used during breastfeeding unless the clinical benefit clearly outweighs the unknown risk to the infant. Given the lack of human data, most clinicians will advise against use while breastfeeding. AUD treatment during breastfeeding should be discussed with your care team, with naltrexone (which has more lactation data) typically considered first.

PCOS and Metabolic Overlap

Women with polycystic ovary syndrome have elevated rates of metabolic dysfunction, insulin resistance, and, in some studies, increased rates of disordered substance use including alcohol. Semaglutide is not approved for PCOS but is sometimes used off-label for metabolic features of the condition. A woman with both PCOS and AUD might have a clinician argue two overlapping rationales for semaglutide, but insurance plans evaluate each indication separately and neither PCOS nor AUD is an approved indication for Wegovy.

Pregnancy, Lactation, and Contraception: Required Reading

Semaglutide is contraindicated in pregnancy. This is a hard stop, not a soft caution.

Animal reproductive toxicity studies showed structural fetal abnormalities and embryo-fetal death at doses below the human exposure level. Human data are limited to case reports and small registry entries; no controlled safety data exist in pregnant women. The FDA label assigns a warning that women of childbearing potential should use effective contraception during treatment and for at least two months after the last dose, because semaglutide's half-life means it persists in serum for approximately five weeks after discontinuation.

If you are trying to conceive, Wegovy should be stopped at least two months before your target conception date. ACOG's clinical guidance on obesity in pregnancy addresses GLP-1 use, recommending discontinuation before conception.

For women of reproductive age pursuing off-label semaglutide for AUD, your prescribing clinician should document contraceptive counseling and your chosen method. Long-acting reversible contraception (IUD or implant) is the most reliable option if you do not wish to become pregnant during treatment.

Alcohol use disorder itself carries significant pregnancy risks independent of medication, including fetal alcohol spectrum disorder. Treating AUD before or during preconception planning is medically important regardless of which agent is used.

How to Have the Conversation With Your Prescriber

Most primary care clinicians have not been trained to prescribe semaglutide for AUD. You will likely need to bring the evidence to the appointment.

What to Bring

• A printed or linked copy of the Hendershot 2024 NEJM Evidence paper
• Your AUD diagnosis documentation (AUDIT score or DSM-5 criteria noted in your chart)
• Your current medications, because semaglutide slows gastric emptying and may alter absorption of oral medications including hormonal contraceptives taken at fixed time windows

Questions Worth Asking

Ask your clinician whether your plan has a medical exception pathway. Ask whether an addiction medicine specialist co-signing the request would strengthen the prior auth. Ask specifically about the STAR trial if you want a monitored, cost-free option.

FDA-Approved Alternatives for AUD

Three medications carry actual FDA approval for alcohol use disorder: naltrexone (oral or long-acting injectable), acamprosate, and disulfiram. A 2023 Cochrane review found that both naltrexone and acamprosate reduce relapse rates compared to placebo. These are covered by most insurance plans and cost substantially less than Wegovy. They are not mutually exclusive with semaglutide if a clinician believes combination treatment is appropriate, but that combination has not been studied in any published trial.

Who This May Be Right For, and Who Should Wait

Semaglutide for AUD may be a reasonable conversation to have with your clinician if you meet most of these criteria:

• You have AUD (mild to severe by DSM-5 criteria) and have tried or cannot tolerate naltrexone, acamprosate, or disulfiram
• You also independently qualify for Wegovy under the obesity indication (BMI of 30 or BMI of 27 with a comorbidity), which at minimum opens the insurance pathway
• You are not pregnant, not breastfeeding, and using reliable contraception if you are of reproductive age
• You can afford $1,100 or more per month out of pocket, or are willing to pursue trial enrollment

You should wait, or choose a different treatment, if:

• You are pregnant or actively trying to conceive
• You are breastfeeding
• You have a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 (both are contraindications listed in the FDA label)
• You have a history of pancreatitis
• Cost is a barrier and you have not yet tried FDA-approved, insurance-covered AUD medications

The evidence supporting FDA-approved AUD medications is far stronger than what currently exists for semaglutide. Starting there is not settling. It is sound clinical reasoning.